Moderna, Pfizer and COVID-19

Moderna COVID Vaccine Technology Struck Down by PTAB
Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s patents for its COVID-19 vaccine technology. The final written decisions remain sealed.
Pfizer convinces US Patent Office to cancel two Moderna COVID-19 vaccine patents
Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U.S. Patent Office tribunal that two patents Moderna accused them of infringing were invalid.
Moderna Scores Legal Victory Over Pfizer, BioNTech in Patent Dispute
MODERNA (MRNA, Financial) secured a major legal win in its COVID-19 vaccine patent dispute with Pfizer (PFE, Financial) and BioNTech (BNTX, Financial). A Dusseldorf cour
Pfizer and BioNTech COVID vaccine broke patent — German court
FRANKFURT - A German court found Wednesday that American pharmaceutical giant Pfizer and German firm BioNTech violated a patent to make their COVID-19 vaccine.Siding with Moderna, an American pharmaceutical firm that brought the case,
German court rules Pfizer, BioNTech violated Moderna's COVID-19 vaccine patent
A German court on Wednesday ruled that Pfizer and its partner BioNTech violated a COVID-19 vaccine patent held by Moderna .
Moderna wins patent lawsuit against BioNTech/Pfizer in German court
A German court ruled on Wednesday that BioNTech and Pfizer violated a Covid-19 patent held by rival Moderna. US-based Moderna had asserted claims for information and damages for infringement of its patent rights in the development of the Covid-19 vaccine.
TipRanks on MSN4h
Moderna’s Stock Soars Amid Insider Confidence
Moderna ( ($MRNA) ) has risen by 17.64%. Read on to learn why. Moderna’s stock has seen a significant rise of 17.64% over the past week, capturing ...
Moderna Eyes 2027 Launch for Cancer Vaccine Developed With Merck
Moderna Inc. expects to launch a personalized cancer vaccine that it’s developing with Merck & Co. by 2027, one of its top ...
Moderna: Patent Litigation Win Masks Underperformance, Unlikely To Pay Out
Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...
Moderna (MRNA) Stock Climbs as CEO and Director Make Strategic Insider Purchases
Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...
Fierce Pharma2d
Pfizer, BioNTech notch US win—and loss in Germany—amid high-stakes patent fight with Moderna
As part of a global web of patent litigation over COVID-19 vaccines and mRNA technology, Pfizer and its partner BioNTech ...
Moderna: Insider Buy Signal
Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities. Explore ...
MRNA Stock: Too High At $35?
Moderna (NASDAQ:MRNA) shares jumped 16% on Wednesday, March 5, following a favorable German court decision that determined ...
Moderna (NasdaqGS:MRNA) Rises 10% Despite US$1 Billion Revenue Drop Prediction
Moderna (NasdaqGS:MRNA) recently experienced a notable 10% price increase over the last week amidst significant legal and financial developments. Genevant Sciences and Arbutus Biopharma have expanded ...
Investor's Business Daily on MSN1d
Why Moderna Stock Has Surged 20% This Week Despite Mixed News
Moderna stock has surged more than 20% this week after regulatory filings showed several executives bought shares on the open ...